Conference Coverage
Conference Coverage
New PCSK9 inhibitor allows 3-month treatment intervals
Recaticimab, an investigational PCSK9 inhibitor, has shown durable lowering of low-density lipoprotein cholesterol with injection frequencies of 1...
Conference Coverage
AI interpretation of CCTA unlocks value of inflammation as CV risk factor
Combined with imaging, artificial intelligence (AI) identifies risk in setting of nonobstructive coronary disease.
Conference Coverage
‘Smart’ stethoscope spots peripartum cardiomyopathy
Finding that 4% of the women in the intervention arm had reduced ejection fraction is “absolutely startling ... and speaks to how important...
Conference Coverage
Cardiologists, patients can talk drug costs
A pilot study shows that an intervention that gives physicians and patients information on out-of-pocket costs for heart failure drugs can help...
Conference Coverage
More evidence of better outcomes with 120–mm Hg BP target
“We are doing very badly in terms of implementation. There is a big gap between science and what’s happening in the real world.”
Latest News
FDA OKs symplicity renal denervation system for hypertension
The Symplicity Spyral system provides a catheter-based approach to denervate the renal arteries using radiofrequency energy.
Latest News
Single injection reduces blood pressure for 6 months: KARDIA-1
Zilebesiran is a subcutaneous RNA interference therapeutic that binds with high affinity to the hepatic asialoglycoprotein receptor, bringing...
Conference Coverage
Alternative antirejection regimen is efficacious in pediatric heart transplant
Results of the head-to-head TEAMMATE trial show the combination of everolimus and low-dose tacrolimus can be considered an alternative to MMF plus...
Conference Coverage
Smartphone app detects voice quality changes indicating worsening heart failure
Early warnings were generated 24-26 days before heart failure events.
Conference Coverage
Promising first results with DNA editing to lower LDL
The first in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial...
Latest News
Albuminuria reduction fuels finerenone’s kidney benefits
Mediation analyses of finerenone trial data show most of the drug’s kidney benefit and a third of its CVD benefit comes from cutting albuminuria...